CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,608 | -39.3% | 5,367 | -24.9% | 0.00% | -50.0% |
| Q2 2023 | $401,457 | +94.3% | 7,151 | +56.5% | 0.00% | +100.0% |
| Q1 2023 | $206,656 | -34.2% | 4,569 | -5.0% | 0.00% | -50.0% |
| Q3 2022 | $314,000 | -3.4% | 4,810 | -10.0% | 0.00% | -33.3% |
| Q2 2022 | $325,000 | +25.0% | 5,347 | +29.1% | 0.00% | +50.0% |
| Q1 2022 | $260,000 | -37.2% | 4,142 | -24.2% | 0.00% | -33.3% |
| Q4 2021 | $414,000 | -46.4% | 5,465 | -20.9% | 0.00% | -50.0% |
| Q3 2021 | $773,000 | -3.9% | 6,909 | +39.1% | 0.01% | -14.3% |
| Q2 2021 | $804,000 | +34.9% | 4,966 | +1.6% | 0.01% | +16.7% |
| Q1 2021 | $596,000 | -73.5% | 4,890 | -66.6% | 0.01% | -76.0% |
| Q4 2020 | $2,245,000 | +139.3% | 14,662 | +30.7% | 0.02% | +92.3% |
| Q3 2020 | $938,000 | +340.4% | 11,220 | +123.7% | 0.01% | +160.0% |
| Q1 2020 | $213,000 | – | 5,015 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |